Cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy (CR-HIPEC) is a locorregional surgical therapy that can be applied in patients with peritoneal-only metastatic disease of primary abdominal malignancies [1], [2]. When integrated in a multimodal treatment, CR-HIPEC is associated with increased overall survival [3], [4], [5], [6], [7], [8]. It is known that in cases of peritoneal-site only relapse, still remaining common (26-65% on appendicular tumors) [9], [10], [11], this procedure may be carried out more than once. Complete cytoreduction is essential for the effectiveness of this procedure, and more than one cytoreductive surgery can be offered in selected patients, particularly in colorectal and appendicular neoplasms [7]. However, there has been little published evidence on short- and long-term results of repeat CR-HIPEC. Several studies, the majority of them small series, have demonstrated benefits in repeating CR-HIPEC in the same patients [3], [12], [13], [14], [15]. The aim of this study was to evaluate the results of repeat CR-HIPEC in patients with peritoneal recurrence.